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Qingyao Huang  1,2 & Michael Baudis  1,2*
In many cancers, incidence, treatment efficacy and overall prognosis vary between geographic 
populations. Studies disentangling the contributing factors may help in both understanding cancer 
biology and tailoring therapeutic interventions. Ancestry estimation in such studies should preferably 
be driven by genomic data, due to frequently missing or erroneous self-reported or inferred metadata. 
While respective algorithms have been demonstrated for baseline genomes, such a strategy has not 
been shown for cancer genomes carrying a substantial somatic mutation load. We have developed 
a bioinformatics tool for the assignment of population groups from genome profiling data for 
both unaltered and cancer genomes. Despite extensive somatic mutations in the cancer genomes, 
consistency between germline and cancer data reached of 97% and 92% for assignment into 5 and 26 
ancestral groups, respectively. Comparison with self-reported meta-data estimated a matching rate 
between 88–92%, mostly limited by interpretation of self-reported ethnicity labels compared to the 
standardized mapping output. Our SNP2pop application allows to assess population information from 
SNP arrays as well as sequencing platforms and to estimate the population structure in cancer genomics 
projects, to facilitate research into the interplay between ethnicity-related genetic background, 
environmental factors and somatic mutation patterns in cancer biology.
Cancer arises from the accumulation of genomic aberrations in dividing cells of virtually all types of proliferat-
ing tissues (somatic variations). The irregular cellular expansion and other hallmarks of cancer can result from 
a plethora of mechanisms affecting multiple cellular processes1. Some oncogenetic pathways can be initiated by 
exogenous factors, e.g. tobacco smoke or ultraviolet radiation2. However, exposure to carcinogenics varies in its 
effects for people from different genetic background, which suggests that somatic mutations can be influenced by 
inherited (“germline”) variations3,4.
Cancer studies have reported significant world-wide variation in incidence and prognosis between ethnicity 
groups5–8. While such differences have been attributed to unequal social and economical circumstances which 
influence risk factors and therapeutic interventions, several studies have shown impact of population specific 
genomic variants with predisposing effects on malignant transformation and phenotypic behaviour9–12. Due to 
the late onset of most cancers, even high-penetrance Mendelian-type variants may not be purged by natural 
selection and can accumulate in particular populations. Such variants may play key roles in cancer development13. 
Notably, mutations on BRCA1/2 genes confer a high risk to develop breast and ovarian carcinomas. Three founder 
mutations in Ashkenazi Jewish population cause the BRCA1/2 mutation prevalence to be 10-fold higher than all 
sporadic mutations in the general population14,15. Mitochondrial aldehyde dehydrogenase (ALDH2) encodes 
an enzyme in alcohol metabolism. One variant, ALDH2*504Lys, which increases risk for alcohol-related liver, 
colorectal and esophageal cancer by alcohol consumption, has 36% prevalence in East Asian populations16,17.
Many other studies have reported prevalent genetic variants in specific population groups which may con-
tribute to the observed disparities in occurrence and prognosis among populations18–20. As patients of European 
ancestry are overrepresented in medical research and clinical studies, we have a biased view on genetic aetiol-
ogy in diseases and available therapeutic approaches may not benefit patients with other genetic backgrounds. 
Studying less explored ancestral backgrounds may lead to discovery of new biological mechanisms and thera-
peutic prospects. Although high-impact monogenic germline variants are rarely expected in cancer, polygenic 
variation models for breast cancer which estimate the combined risk profile of multiple loci have been developed, 
suggesting the potential of exploring genome-wide risk profiles21. Another study on germline background of 
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cancer genomes has also identified disease-associated chromosomal regions from only seven individual samples 
with linkage mapping22. This type of studies can be conducted population-wise, with sufficient number of samples 
from the same population or ethnicity group.
With the increasing number of available genome profiles and the decreasing cost to genotype clinical samples, 
the stratification between patients’ genetic backgrounds has become feasible with the promise to guide therapeu-
tic strategies and improve the clinical prognoses. Since several studies have demonstrated the relevance of consid-
ering an individual’s genomic origin for preventive screening (reviewed in Foulkes et al.15), information about the 
population background of cancer patients may be an additional factor for individual therapeutic decisions as well 
as for the stratification of clinical study cohorts. A meta-analysis addressing the interplay between genetic back-
ground, cancer development and therapeutic responses is desirable, not only for robust statistical associations in 
molecular target identification, but also for the rational design of studies incorporating informative biosamples.
For many data repositories, “population group” of a sample can be assumed based on a geographical location 
associated with the sample. Alternatively, a self-reported “race” category is commonly used in the U.S. census 
data23,24. A biosample’s geographic origin is often approximated using the location of the study’s research facil-
ity or the contact address of its main authors25. However, while these data can be easily retrieved, they may not 
provide an accurate representation of patients’ origins for the purpose of population-specific ancestry mapping. 
Self-reported data are often inconsistent across studies, vague in category description (e.g. “white”, “black” v.s. 
“Caucasian”, “African”) and misleading when patients have incomplete awareness of the migration and admixture 
histories of their ancestors. Overall, when associating oncogenic molecular signatures with germline variations, 
information from the above sources lacks in relevant detail and consistency.
A better approach to population assessment would be the computational estimate of ancestry with 
population-specific genomic variants. This has been shown previously for germline profiles, achieving 90% 
accuracy to distinguish three populations, African American, Asian and Caucasian, by using as few as 100 
population-diverging single nucleotide polymorphisms (SNPs)26, and nowadays is a standard methodology with 
claimed better granularity behind a number of commercial “ancestry” services, e.g. 23andme.com, myheritage.com 
and ancestry.com. We hypothesise that a similar strategy can be applied to cancer genome data, despite the addi-
tional cancer-related somatic mutations which leads to both information loss (e.g. large scale homozygous or allelic 
deletions) and added noise (e.g. somatic mutations masking germline variants). An example of a cancer genome 
containing copy number loss and copy-neutral loss of heterozygocity (CN-LOH) events and its paired normal sam-
ple is shown in Fig. 1. It is a typical case of altered genome with copy number loss (blue arrow) with CN loss regions 
partly recovered by doubling of the second allele (CN-LOH, black arrow) at multiple genomic locations. In addition 
to a general test of feasibility of inferring population background from the noisy cancer genome data, we continue 
with benchmarking population mapping procedures for heterogeneous datasets from different genotyping plat-
forms, with the aim of integrating cross-platform cancer genotyping data for meta-analysis.
Figure 1. CNV tracks for a paired normal/cancer samples deposited in GEO with sample IDs GSM276881 and 
GSM276880. GSM276880 is a glioblastoma sample. GSM276881 is its peripheral blood control. The CNV tracks 
are consisted of two panels. Upper panel indicates the total copy number, represented by logR ratio 
(log copy number
reference copy number2
 at any probe) Namely, logR = 0 indicates a position with normal two copies, logR > 0 
indicates a copy number gain and logR < 0 indicates a copy number loss. Lower panel indicates the allele 
specific copy number, represented by B-allele frequency (BAF, No B allele copy
Total copy number
. ). Any given SNP position can have 
a value between 0 and 1. A line at 0.5 indicates a heterozygous region. Compared to the unaltered genome (A), 
the cancerous counterpart (lower) has copy number loss in chr8, 10p, 18, 19qter, 22q and copy-neutral loss of 
heterozygocity in chr9,12q, accounting for 18.2% of genome.
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Results
We developed SNP2pop pipeline to assign genomic data to ancestral groups defined by 1000 Genomes Project27, 
i.e. five continental groups and 26 population groups, respectively: 1. Admixed American (AMR) includes: 
Colombians from Medellin, Colombia (CLM), Mexican Ancestry from Los Angeles USA (MXL), Peruvians from 
Lima, Peru (PEL) and Puerto Ricans from Puerto Rico (PUR); 2. African (AFR) includes: African Caribbeans in 
Barbados (ACB), Americans of African Ancestry in SW USA (ASW), Esan in Nigeria (ESN), Gambian in Western 
Divisions in the Gambia (GWD), Luhya in Webuye, Kenya (LWK), Mende in Sierra Leone (MSL), and Yoruba in 
Ibadan, Nigeria (YRI). 3. East Asian(EAS) includes: Chinese Dai in Xishuangbanna, China (CDX), Han Chinese 
in Beijing, China (CHB), Southern Han Chinese (CHS), Japanese in Tokyo, Japan (JPT) and Kinh in Ho Chi 
Minh City, Vietnam (KHV); 4. European (EUR) includes Utah Residents with Northern and Western European 
Ancestry (CEU), Finnish in Finland (FIN), British in England and Scotland (GBR), Iberian Population in Spain 
(IBS) and Toscani in Italia (TSI); 5. South Asian (SAS) includes: Bengali from Bangladesh (BEB), Gujarati Indian 
from Houston, Texas (GIH), Indian Telugu from the UK (ITU), Punjabi from Lahore, Pakistan (PJL) and Sri 
Lankan Tamil from the UK (STU).
We benchmarked this tool with various normal and cancer samples from independent datasets to demonstrate 
the feasibility and reliability of this approach.
Cross-platform benchmarking. We first used the original data from 1000 Genomes to validate the level 
of resolution needed for accurate population assignment from the pipeline. Taking the sequencing data of 2504 
samples and extracting the SNPs from the nine genotyping platforms of interest gave rise to the dataset in this 
benchmarking experiment. The number of SNPs per platform ranged from 10 204 (Affymetrix Mapping 10 K) to 
934 946 SNPs (Affymetrix Genome Wide SNP 6). For all nine genotyping platforms (of seven levels of resolution), 
the model performed equally well in capturing the informative SNPs and predicting the population category. The 
assignment of 2504 samples from 1000 Genomes Project into 5 continental groups had low margins of error for 
all genotyping platforms (Fig. 2). To benchmark the separation of 26 groups, we applied a repeated cross valida-
tion (CV) on both random forest and multinomial linear regression model for the assignment task. Here, the CV 
accuracy rate ranged between 75–85% depending on platform resolution. When combining pairs of frequently 
mixed groups into 10 categories, a CV accuracy rate rose to >99% (Fig. S3 and Table S3).
Benchmarking normal genome profile assignment with HapMap data. To validate the accuracy 
of our tool to map population origins from non-cancer SNP datasets, we used 112 samples from the HapMap 
project28 which is not included in the reference set, but acquired through GEO. After a further examination for 
family relatedness, we excluded 67 first-degree relatives to samples from 1000 Genomes project. By HapMap 
metadata, the 45 samples came from three distinct population groups (at the level of 26 population groups, from 
three different super population groups): CEU, CHB and YRI. Except for one sample with “CEU” label predicted 
as “AMR”, the assignment of the rest of samples all matched their ethnicity information indicated in the meta-data 
(Table 1).
Paired cancer-normal comparison. One of the highlights in this tool lies in the determination of popu-
lation origin from cancer genome profiles carrying various acquired genomic aberrations. Since the non-cancer 
samples could be correctly assigned according to HapMap categories, we then validated the cancer genome 
based assignments in samples where normal genome profiles of the same patients (e.g. from peripheral blood or 
Figure 2. Estimating the model accuracy with reference samples with SNPs extracted from genotyping 
platforms of seven different resolution levels. Here we use margin as an estimator for the accuracy of the 
prediction model with random forest classifier output. It is defined as difference between the proportion of 
votes for the correct class minus maximum proportion of votes for the other classes. A positive value indicates 
correct prediction. For 2504 samples in the 1000 Genome Project, the number of incorrectly predicted samples 
ranged from 4 to 11, corresponding to an error rate of 0.16% to 0.4%. Note that this is cross validation error on 
reference dataset, rather than real data.
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non-cancer tissue samples) were available as reference. We performed the validation with two independent data 
sources — GEO and TCGA project.
GEO data. From the GEO repository, we retrieved all paired normal and cancer samples from 1145 individuals 
and compared the outcome of the population assignment. When including all 1145 individuals, 92.1% of the 
normal samples matched with paired tumor samples. With an increasing confidence score, the matching accuracy 
increased (Table S4). The error rate dropped from 15.9% to 1.5 % comparing samples with score range “0.2–0.4” 
to those with “0–0.2”. After setting a threshold of normal samples with score >0.2, 95.8% accuracy could be 
achieved for the remaining 688 individuals. When also setting the score threshold for cancer samples to >0.2, 
98.9% of the 647 remaining samples could be matched correctly (Fig. 3A). This comparison suggested a high 
accuracy rate in population assignment for cancer samples and an increase in the level of accuracy with a lower 
admixture background of the individual.
TCGA data. We used the genomic array profiling data from TCGA project, all of which originate from the 
array platform Genome Wide SNP 6. We extracted all 18380 samples (of 9190 individuals), where a normal tissue 
control for the respective tumor sample was available. 8924 out of 9190 (97.1%) individuals had matched tumor/
normal categories. After setting a threshold of normal samples with score >0.2, 98.4% accuracy (8413 out of 8549 
individuals) can be achieved. When also setting the score threshold for cancer samples to >0.2, 8195 of the 8216 
(99.7%) remaining samples could be matched correctly (Fig. 3B). The score and error relation was depicted in 
the Table S5.
For population assignment into 26 groups, 8522 out of 9190 (92.7%) pairs had matching categories (Fig. S4). 
With the same score thresholding as described above, the accuracy increased to 97% (7374 out of 7602) and 
99.1% (6948 out of 7010) respectively.
CEU CHB YRI
AFR 0 0 14
AMR 1 0 0
EAS 0 6 0
EUR 24 0 0
Table 1. Comparison of HapMap metadata and predicted population group. Each column indicates HapMap 
population labels. Each row indicates the label predicted by the tool. CEU stands for Utah residents with 
Northern and Western European ancestry from the CEPH collection, CHB stands for Han Chinese in Beijing, 
China. YRI stands for Yoruba in Ibadan, Nigeria; AFR stands for African; AMR stands for Admixed American; 
EAS stands for East Asian; EUR stands for European.
Figure 3. Accuracy of assignment with paired tumor and normal samples from GEO and TCGA project. 
647 (score > 0.2) individuals from GEO (A) and 8216 (score > 0.2) individuals from TCGA project (B) with 
paired tumor and normal samples with paired tumor and normal samples were examined. The columns are the 
prediction groups for the normal samples and the color codes indicate the proportion of each group predicted 
from their respective cancer samples.
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Modification of SNP status during carcinogenesis. We further scrutinized the source of noise and informa-
tion loss during carcinogenesis. Using the same dataset, we performed a SNP-by-SNP comparison between the 
paired normal and cancer samples and summarized the SNPs which changed from heterozygous to homozygous 
(Het2Homo), from homozygous to heterozygous (Homo2Het) or stayed identical (Fig. S5). The Het2Homo (6.3% 
on average) transition occurred in case of allele loss or copy-neutral loss of heterozygocity and constituted the 
larger part to noise in cancer samples. The Homo2Het (5.6% on average) transition could come from loss of both 
alleles causing BAF to appear at 0.5 or less frequently when somatic point mutations coincide with germline pol-
ymorphism sites. In this section, We benchmarked the cancer/normal assignment consistency with presence of 
these two types of SNP status modifications. We also indirectly addressed the issue of tumor sample purity here, 
as mixed cancer/normal samples would be assigned to same categories as either of the pure cell populations.
Comparison with self-reported ethnicity metadata. To assess the overall accuracy of self-reported 
population information, we compared the meta-data from GEO and TCGA with our benchmarked results.
GEO data. We retrieved a total of 1724 samples with intelligible self-reported metadata from GEO. We extracted 
the population-implying keywords, which formed nine groups: “african”(92), “african-american”(59), “black”(6), 
“caucasian/european”(1472), “white”(40), “asian”(23), “chinese”(12), “hispanic”(12) and “native american”(2) 
(Fig. 4). Specifically, “african” and “african-american” samples were mostly assigned to “AFR” group (91.3% and 
93.6% respectively). The 1472 “caucasian/european”-labeled samples were assigned to “EUR” (90.2%) with small 
fraction assigned to “AFR”(4.6%) or “AMR”(5.0%). 11 out of 12 “hispanic” samples were assigned to “AMR” with 
one as “EUR”. All 40 “white” samples were assigned to “AMR”. These 40 samples derived from the same study, so 
the patients were likely from a similar ethnicity background and reported as “white” by the study. The “asian” 
samples were mostly assigned to “EAS” group (19/23). All 12 “chinese” samples were correctly assigned to “EAS”. 
Two ‘native-american’ samples were both assigned to “EUR”. Counting all samples, a meta-data matching rate of 
Figure 4. Accuracy of assignment with self-report metadata from GEO and TCGA project. (A) The 
composition of assigned super population groups of 1724 samples from GEO with extracted population/
ethnicity metadata in nine groups: “african”(92), “african-american”(59), “black”(6), “caucasian/
european”(1472), “white”(40), “asian”(23), “chinese”(12), “hispanic”(12) and “native american”(2). (B) The 
composition of assigned super population groups of 9190 samples in six “race” categories from TCGA meta-
data: “American Indian or Alaska native”(23), “Asian”(612), “Black or African American”(793), “Native 
Hawaiian or other Pacific Islander”(12), “White”(6600) or “Not Reported”(1150).
6Scientific RepoRtS |         (2020) 10:4846  | https://doi.org/10.1038/s41598-020-61854-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
88.3% was achieved. This indicated the existing heterogeneity in ethnicity description across studies and a certain 
degree of inaccuracy in self-reported ethnicity information.
TCGA data. From the test of paired cancer/normal samples in TCGA, we also compared our results of 9190 
normal samples with the “race” attribute provided by the metadata. There, six categories were distinguished: 
“American Indian or Alaska native”(23), “Asian”(612), “Black or African American”(793), “Native Hawaiian or 
other Pacific Islander”(12), “White”(6600) or “Not Reported”(1150). The fraction of assignment results in each 
of these categories were shown in the bar plots in Fig. 4B). Most samples reported as “white” were assigned to 
“EUR”(91.4%) with 7.7% “AMR”; Most samples reported as “Black or African American” were assigned to “AFR” 
(95.6%) with “AMR” (3.0%) and EUR (1.0%); The “Asian”-labeled samples were composed of 90.5% “EAS” and 
8.2% “SAS”. 14 out of the 23 “American Indian or Alaska Natives”-labeled samples were assigned to “AMR” and 
5 to “EUR”. In the 12 “Native Hawaiian or other Pacific Islanders” samples, 10 were assigned to “EAS” and 2 
to “AMR”. The samples were also assigned to one of the 26 population groups (Fig. S6), but there was no more 
meta-data for a comparison on this level. If we expect the following three “race” groups to match the assignment: 
“White” to “EUR”, “Black or African American” to “AFR” and “Asian” to “EAS” and “SAS”, then a total matching 
rate of 92.4% was achieved with 95.6% in African group, 98.6% in Asian group and 91.4% in European group. 
Despite the high matching percentage on the level of super population group in the self-report groups with large 
sample numbers (“White”, “Black or African American” and “Asian”), one may still argue that with the prediction 
outcome from our tool, the “race” information defined in the project could be well complemented and adapted 
for a quantitative measure for genetic background assessment.
Discussion
The presented method resolves two issues that have been missing in the earlier approaches to estimate population 
structure from genotyping data: 1. it allows the integration of platforms with heterogeneous, non-overlapping 
SNP positions for cross-platform meta-analysis; 2. it confirms the possibility of deriving the population origin 
using data from aberrant cancer genomes in addition to those of unaltered genomes.
In our study, we establish the robustness of deriving population despite platform heterogeneity by 
cross-platform benchmarking. We show that for all the genotyping platforms used in the study, our pipeline 
achieves similarly high prediction accuracy, even for the lowest resolution platform with around 10 000 SNPs. 
This helps to integrate genotyping data generated with different platforms for meta-analysis, where the heteroge-
neity in resolution does not pose great impact on the parameters of interest (e.g. cancer copy number variation 
studies).
We demonstrate the feasibility of incorporating aberrant cancer genomes in a step-wise manner. First, we 
benchmark the method using samples with unaltered genomes (non-cancer) which are different from the refer-
ence dataset, and show a high matching accuracy. In addition, we simulate different levels of LOH from unaltered 
genomes and observed mis-assignment or decrease of confidence score only at high coverage of LOH (LOH in 
>60% genome) (Fig. S7). Then, we employ paired normal/cancer samples and benchmark the assignment con-
sistency between them. With two independent data resources (GEO and TCGA), we show that the population 
group estimated from unaltered genome of the same individual matches that from the aberrant cancer genome 
with a high accuracy rate.
From the paired sample comparison, we do observe a certain degree of mismatches. These often occur in sam-
ples with a highly admixed background (indicated by lower score), rather than related to whether they are normal 
or cancer samples as discussed above. Furthermore, the mismatch occurs mostly between the AMR and EUR 
labels, which is partly expected as the 1000 Genomes Project describes “AMR” group as “Admixed American”. 
Clearly defining indigenous American population as reference is impractical due to the admixture events in the 
last hundreds of years in South America. Such admixture events inevitably pose a challenge when establishing sta-
ble reference groups for assessing the impact of population background on secondary phenotypes like mutational 
patterns in cancer. As many human populations are still limitedly represented or missing and major contributions 
to human genetic variations are emerging29, genomic population models will be amenable for re-assortment. 
Accordingly, our SNP2pop tool allows user-specified labeled reference data upload and assign population labels 
to the unknown samples according to the provided reference groups.
To conclude, we have developed a bioinformatics tool to assign population group based on SNP genotyp-
ing array data. We demonstrate its feasibility and accuracy on cancer samples, where somatic mutations may 
obfuscate part of the ancestry related SNP signal. This work can facilitate the re-analysis and meta-analysis of 
available cancer data by grouping samples with similar genetic background to study the potential genetic predis-
position to cancer. In addition, our method provides the basis for subsequent haplotype phasing and refinement 
of genomic landscape for emerging somatic variation. With this tool, researchers will be able to integrate cancer 
genome profiling data from multiple resources to better assess the contribution of population background in 
population-specific mutation patterns occurring in cancer.
Methods
We used whole genome sequencing data from the 1000 Genomes Project27 as reference data, which contains 2504 
individuals from 26 population groups out of 5 continental groups. Allele information for SNP positions meas-
ured by the 9 selected array platforms was retrieved. In order to achieve between-study consistency for selection 
of informative SNPs, we used admixture model30 to pre-compute parameters optimized for each genotyping 
platform based on the reference data. The allele frequency and ancestry fraction parameters were projected to the 
incoming cancer dataset of the same platform. Then, by applying a random forest classification, we assigned the 
population label to the highest voted group and produced a score for the difference between highest and second 
highest percentage votes. The overview of the pipeline is shown in Fig. 5. The tool is accessible for direct use as 
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a Docker image “https://hub.docker.com/r/baudisgroup/snp2pop” on DockerHub and its source codes can be 
found on Github in project “https://github.com/baudisgroup/snp2pop”.
Data preparation. Reference data preparation. The SNP positions for each platform were acquired from 
Affymetrix annotation files. The allele information was extracted for all positions with vcftools31. The 12 mislabe-
led or admixed individuals were removed from the reference dataset, leaving 2492 individuals. The SNP positions 
with duplicated rsIDs in annotation files were removed. The reference or alternative strands were swapped to 
match the SNP array annotation. Sites with minor allele frequency (MAF) of less than 5 percent were removed. 
SNPs were subsequently pruned for independence using PLINK 1.932. Specifically, a sliding window of 50 bp and 
a 5 bp shift of window at each step of pruning, with the variance inflation factor (VIF = 1/(1 − R2), with R2 equal 
to the multiple correlation coefficient for a SNP regressed on all other SNPs) at 1.5. The result files were stored as 
PLINK output for each platform in .bed, .bim and .fam formats, of which the .bim files were used to extract SNP 
positions from target data.
Target data preparation. The SNP array data were processed with ACNE R package33 to extract allele-specific 
copy numbers as B-allele frequencies (BAF). SNPs were labeled as homozygous A, heterozygous AB or homozy-
gous B by the BAF value in ranges 0–0.15, 0.15–0.85 or 0.85–1, respectively, to allow both for noise and expected 
aneuploidy in the biosamples.
Data used for benchmarking are accessed through arrayMap database34, using a collection of re-processed 
genotyping series from the Gene Expression Omnibus (GEO) repository35, and the TCGA data repository36 from 
https://cancergenome.nih.gov. The samples deposited in the former were submitted by individual research stud-
ies, whereas the latter coordinated cancer genome data generation and processing with centralized protocols.
Admixture model. While many approaches use principle component analysis (PCA) to select informative 
SNPs for population assignment, deriving these SNPs prior to clustering methods results in varying sets of SNPs 
between datasets. Here, we used the reference panel to train an admixture statistical model30, to derive the allele 
frequency in theoretical ancestor groups for each SNP. The number of theoretical ancestor groups (K) was chosen 
to be 9 by cross-validation. The ancestry fraction plot for reference individuals demonstrates a proper informa-
tion extraction to distinguish the five continental categories. By projecting the model parameters to a new sample 
with the corresponding platform, a robust and consistent output with 9 ancestry fractions was generated. The 
ratio of the 9 fractions in each individual in the reference data of 26 population groups for each platform is shown 
in Fig. S1.
Random forest label assignment. The nine ancestry fractions from the reference population were used 
to build a random forest model in each platform to predict the 26 population categories. The score was calcu-
lated as the difference in percentage votes between the best and the second best predicted labels. We performed 
repeated cross validation experiments (5-fold cross validation with 10 repetitions), and discovered twelve indi-
viduals assigned into a category different from the labels defined in their meta-data, which might occur due to a 
platform-specific detection of rare alleles that segregate in these samples. They were removed from reference list 
of the model. Finally, 2492 samples were used as training set in the classification model (removed IDs and infor-
mation are found in Table S1). We compared random forest (RF) learning method with a classical multinomial 
Figure 5. Pipeline of our tool to derive population assignment for individual cancer samples. The development 
workflow of the tool starts with retrieving the sequencing data from 1000 Genomes Project, removing IDs with 
admixture origin, extracting SNPs according to the genotyping array platforms and removing SNPs in linkage 
disequilibrium (LD). The generated PLINK files are stored as an intermediate reference file set. This file set 
is used further to train an admixture model with the model parameter matrix (allele frequency and ancestry 
fraction) stored for reference. Finally, a random forest classification is trained for the reference data based on 
their annotated population labels. These pre-computation steps are the basis of the tool, which saves time and 
preserves inter-study consistency. Now, when the new genotyping data comes in, the tool will assign the allele 
by B-allele frequency (BAF), check for the reference/alternative base for each SNP to match the reference data, 
assign the missing alleles (homozygous SNP from incoming data, thereby alternative base not available) based 
on reference SNP annotation. When the data is cleaned and compatible, the tool will use the pre-computed 
model parameters to analyze the admixture in the incoming dataset. Finally, with the model output, the 
population group of the incoming data is assigned. Users can choose to output the model parameters as well as 
the population groups.
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linear regression (MLR) model in terms of performance and computation time. The computation time is 3–5 fold 
slower than MLR (Table S2) but the performance in terms of accuracy is moderately higher (Fig. S2). The classi-
fication strategy used in the tool is first getting votes for all 26 population groups, and generating a highest vote 
group as the prediction result. Then, users have options to further generate a prediction out of 5 super-population 
groups or 10 broader population groups as described in Section “Cross-platform benchmarking”, combining 
votes of groups belonging to the same super-population or broader population group, and output the group with 
highest vote as the prediction outcome, and a score which allows for closer scrutiny for potential admixtures.
Data availability
The docker version of the tool is provided in DockerHub (hub.docker.com/r/baudisgroup/snp2pop). The code is 
available through the repository at github.com/baudisgroup/snp2pop.
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Figure S1. The fraction or contribution of theoretical ancestors (k=9) in reference individuals from 1000 Genomes
Project with regard to nine SNP array platforms. The x-axis are individual samples, grouped by their respective population.
Groups belonging to the same continent/superpopulation are placed neighboring to each other: AFR (1-7), SAS (8-12), EAS
(13-17), EUR (18-22), AMR (23-26).
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Figure S2. Percentage of accurate prediction with multinomial linear regression (MLR) model and random forest
(RF) model into 26 population groups defined in 1000 Genomes Project.
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Figure S3. Percentage of accurate prediction with multinomial linear regression (MLR) model and random forest
(RF) model into 10 population groups defined by the classification ambiguity between 26 groups. The frequently mixed
groups are merged into one, leaving 10 out of 26 groups. See Supplementary Table S3 for the merged groups.
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Figure S4. Agreement of assigned population groups between paired tumor and normal samples in TCGA project
on the level of 26 population groups.
0
200
400
600
0 25 50 75 100
% SNPs
co
u
n
t
variable
Identical
Homo2Het
Het2Homo
Figure S5. Percentage of SNPs in the genotyping arrays that stay identical or changed status. (Homo2Het:
homozygous to heterozygous or Het2Homo: heterozygous to homozygous) between paired cancer and normal samples.
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Figure S6. The composition of assigned population groups in six “race" categories from TCGA meta-data on the
level of 26 population groups.
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Figure S7. The relation of correct assignment rate (blue) and confidence score (red) at different levels of LOH
coverage by simulation. In the simulation, LOH were introduced at randomly chosen 10, 20, . . . , 90, 95 and 98% of
genomic SNP positions. Original data come from 1000 Genomes project where individual population groups are taken out of
reference set and tested for assignment performance with simulation. LWK, FIN, JPT and GIH groups are removed for this test
as they are different from other population groups in the same continental group.
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Suppl. Tables: Enabling population assignment from cancer genomes with SNP2pop
Table S1. 12 IDs were removed from the reference set for the final prediction model due to high admixture background.
Sample.name Sex Biosample.ID Population.code Superpopulation.code
HG00373 female SAME124749 FIN EUR
HG01275 female SAME123002 CLM AMR
NA20299 female SAME124381 ASW AFR
NA20314 female SAME125304 ASW AFR
NA19921 female SAME124712 ASW AFR
HG01241 male SAME125065 PUR AMR
NA19625 female SAME123655 ASW AFR
NA19679 male SAME122796 MXL AMR
HG01108 female SAME123103 PUR AMR
HG01242 female SAME125064 PUR AMR
HG01438 female SAME124971 CLM AMR
NA20274 female SAME123615 ASW AFR
Table S2. Computation time per cross validation run with multinomial linear regression (MLR) model and random forest (RF)
model with respect to the number of prediction output groups.
platform No.prediction labels MLR RF
CytoScan750K_Array 5 1.57 13.9
CytoScanHD_Array 5 1.57 13.8
GenomeWideSNP_6 5 1.69 13.6
Mapping10K_Xba142 5 1.7 14.5
Mapping250K_Sty 5 1.59 13.9
Mapping50K_Hind240 5 1.54 14.1
CytoScan750K_Array 10 3.55 15.6
CytoScanHD_Array 10 3.48 15.5
GenomeWideSNP_6 10 3.56 15.6
Mapping10K_Xba142 10 3.96 17.1
Mapping250K_Sty 10 3.37 15.1
Mapping50K_Hind240 10 3.56 15.7
CytoScan750K_Array 26 10.2 32
CytoScanHD_Array 26 10.3 30.8
GenomeWideSNP_6 26 10.4 30.7
Mapping10K_Xba142 26 10.2 35.8
Mapping250K_Sty 26 10.3 31.9
Mapping50K_Hind240 26 10.3 33.2
Table S3. 10 groups can be distinguished from each other, based on the platform-derived SNPs. AAfr: West
Africa+Caribbeans+African American; WCAfr: West Coast Africa
AAfr South Asia East Asia Central Europe South America WCAfr Finnish Japan Luhya South Europe
ACB BEB CDX CEU CLM GWD FIN JPT LWK IBS
ASW GIH CHB GBR MXL MSL TSI
ESN ITU CHS PEL
YRI PJL KHV PUR
STU
7/8
Table S4. Assignment concordance between paired samples in relation to assignment score range for 1145 paired cancer and
normal samples from GEO.
score_range No.sample mismatch error_rate
(-0.001,0.2) 527 84 0.1594
(0.2,0.4) 403 6 0.0149
(0.4,0.6) 65 1 0.0154
(0.6,0.8) 126 0 0
(0.8,1) 98 0 0
Table S5. Assignment concordance between paired samples in relation to assignment score range for 9190 paired cancer and
normal samples from TCGA.
score_range No.sample mismatch error_rate
(-0.001,0.2) 974 245 0.2515
(0.2,0.4) 490 17 0.0347
(0.4,0.6) 387 3 0.0078
(0.6,0.8) 1961 0 0
(0.8,1) 5378 1 2.00E-04
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